Eric Chang

Eric Chang has extensive experience in equity research and corporate development, particularly within the biotechnology sector. Notable roles include Director of Equity Research at Oppenheimer & Co. and Associate at JMP Securities LLC and Bank of America, where a strong focus on biotechnology was maintained. Eric Chang also served as Executive Director of Corporate Development at Gilead Sciences, leading inflammation and fibrosis partnering and M&A efforts, alongside overseeing corporate strategy and global product planning. In addition, Eric Chang was Vice President of Corporate Development at Star Therapeutics, managing a rare disease portfolio, and held various positions within Bank of America Merrill Lynch. Eric Chang holds a Bachelor of Science from Columbia University and an MBA from the University of California, Berkeley, Haas School of Business.